Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Tiziana Pharma
Tiziana Pharma
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Tiziana announces positive PET scan results with intranasal Foralumab in patients with na-SPMS
Five out of six patients in FDA authorised expanded access programme are showing a qualitative reduction in microglia activation (a key biomarker being observed)
Manufacturing
Tiziana Life Sciences appoints Chief Development Officer
William A. Clementi will take up the role of Chief Development Officer, which will become effective as of September 1 2023
Research & Development
Tiziana develops novel treatment for COVID-19 patients using anti-interleukin-6-receptor mAbs
Company has filed patent application in support of treatment of COVID-19 utilizing anti-il6r via inhaled delivery
Research & Development
Tiziana strengthens unique research focus by appointing Dr Kunwar Shailubhai CEO
Pharmaceutical
Tiziana Life Sciences appoints Arun Sanyal to its Scientific Advisory Board
Arun Sanyal is a professor and a key opinion leader in liver diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Ingredients
Tiziana Life Sciences in-licenses NI-1201, a fully human anti-IL-6R monoclonal antibody
Exclusive worldwide license expands therapeutic pipeline in key immunological areas
Research & Development
Tiziana acquires bio-repository from Shardna and establishes Sardinian subsidiary LonGevia
Aims to further enhance and develop its portfolio using data from the biobank and genomics research
Subscribe now